Tower Research Capital LLC TRC Boosts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tower Research Capital LLC TRC lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 111.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,458 shares of the medical equipment provider's stock after purchasing an additional 8,691 shares during the quarter. Tower Research Capital LLC TRC's holdings in Zimmer Biomet were worth $1,738,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in ZBH. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet during the fourth quarter worth about $25,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $39,000. OFI Invest Asset Management acquired a new position in Zimmer Biomet during the fourth quarter worth $40,000. SRS Capital Advisors Inc. boosted its position in Zimmer Biomet by 146.9% during the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after purchasing an additional 285 shares in the last quarter. Finally, Atala Financial Inc acquired a new stake in Zimmer Biomet in the fourth quarter valued at $51,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Up 0.2 %

Shares of Zimmer Biomet stock traded up $0.19 during trading hours on Monday, reaching $101.70. The stock had a trading volume of 261,302 shares, compared to its average volume of 1,981,168. Zimmer Biomet Holdings, Inc. has a 1 year low of $93.10 and a 1 year high of $123.96. The firm has a 50 day simple moving average of $105.81 and a two-hundred day simple moving average of $106.61. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $20.12 billion, a price-to-earnings ratio of 22.85, a P/E/G ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio is presently 21.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Stifel Nicolaus increased their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial reissued a "hold" rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $124.15.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.95% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.